Health Technology Assessment of Carbon-ion Beam Radiotherapy: A Systematic Review of Clinical Effectiveness and Safety for 54 Oncological Indications in 12 Tumour Regions. G. GOETZ, M. MITIC, T. MITTERMAYR, C. WILD (Vienna; Krems, Austria) .......................................................... 1635


The Emerging Role of Calcium-activated Chloride Channel Regulator 1 in Cancer. D. HU, D. ANSARI, M. BAUDEN, Q. ZHOU, R. ANDERSSON (Wenzhou, PR China; Lund, Sweden) .......................................................... 1661

Breast Radiotherapy and Early Adverse Cardiac Effects. The Role of Serum Biomarkers and Strain Echocardiography. A. GKANTAIFI, C. PAPADOPOULOS, D. SPYROPOULOU, M. TOUMPOURLEKA, G. ILIADIS, D. KARDAMAKIS, M. NIKOLAOU, N. TSOUKALAS, G. KYRGIAS, M. TOLIA (Thessaloniki; Patras; Athens; Larissa, Greece) ........................................................................................................ 1667


Contents continued on the back cover
Editorial Board

P. A. ABRAHAMSSON, Malmo, Sweden
B. B. AGGARWAL, San Diego, CA, USA
T. AKIMOTO, Kawasaki, Chiba, Japan
P. Z. ANASTASSIDIS, Jacksonville, FL, USA
A. ARCHIBALD, San Antonio, TX, USA
J. P. ARMAND, Toulouse, France
V. I. AVRAMIS, Los Angeles, CA, USA
D. T. BAU, Taichung, Taiwan, ROC
G. BAUER, Freiburg, Germany
E. E. BAULIEU, Le Kremlin-Bicêtre, France
E. J. BENZ, Jr., Boston, MA, USA
J. BERGH, Stockholm, Sweden
F. T. BOSMAN, Lausanne, Switzerland
M. BOUVET, La Jolla, CA, USA
J. BOYD, Miami, FL, USA
G. BROKDA, Monza, Italy
O. S. BRULAND, Oslo, Norway
J. M. BUATTI, Iowa City, IA, USA
M. M. BURGER, Basel, Switzerland
M. CARBONE, Honolulua, HI, USA
C. CARLBERG, Kuopio, Finland
J. CARLSSON, Uppsala, Sweden
A. F. CHAMBERS, London, ON, Canada
P. CHANDRA, Frankfurt am Main, Germany
L. CHENG, Indianapolis, IN, USA
J. G. CHUNG, Taichung, Taiwan, ROC
R. CLARKE, Washington, DC, USA
E. DE CLEERCO, Leuven, Belgium
W. DEN OTTER, Amsterdam, The Netherlands
E. P. DIAMANDIS, Toronto, ON, Canada
G. TH. DIAMONDPOULOS, Boston, MA, USA
L. EGEVAD, Stockholm, Sweden
D. W. FELSHER, Stanford, CA, USA
A. J. FERNANDEZ-POL, Chesterfield, MO, USA
I. J. FIDLER, Houston, TX, USA
A. P. FIELDS, Jacksonville, FL, USA
H. FU, Atlanta, GA, USA
B. FUCHS, Zurich, Switzerland
D. FUKUMURA, Tokyo, Japan
D. FUJISAWA, Boston, MA, USA
G. GABBANI, Geneva, Switzerland
R. GANAPATHI, Charlotte, NC, USA
A. F. GAZDAR, Dallas, TX, USA
A. GIORDANO, Philadelphia, PA, USA
G. GITSCH, Freiburg, Germany
M. GNANT, Vienna, Austria
R. H. GOLDFARB, Guilford, CT, USA
A. HELAND, Oslo, Norway
I. HELSON, Quakertown, PA, USA
R. HENRIKSSON, Umeå, Sweden
R. M. HOFFMAN, San Diego, CA, USA
S. C. HANWAR, New York, NY, USA
J. V. JOHANNESSEN, Oslo, Norway
R. JONES, London, UK
B. KAINA, Mainz, Germany
P. L. KELKOMPU-LIHTIEN, Tampere, Finland
D. G. KIEBACK, Schleswig, Germany
R. KLAPDOR, Hamburg, Germany
H. KOBAYASHI, Bethesda, MD, USA
S. D. KOTTARIDIS, Athens, Greece
G. R. F. KRUEGER, Köln, Germany
Pat M. KUMAR, Manchester, UK
Shant KUMAR, Manchester, UK
O. D. LAERM, Bergen, Norway
F. J. LEJEUNE, Lausanne, Switzerland
S. LINDER, Linköping, Sweden
L. F. LIU, Piscataway, NJ, USA
I. SUNDGREN, Umeå, Sweden
Y. MAEHA, Fukushima, Japan
J. MAHER, London, UK
J. MARESCAUX, Strasbourg, France
J. MARK, Skivde, Sweden
S. N. MARTIN, Baltimore, MD, USA
S. MITRA, Houston, TX, USA
S. MIYAMOTO, Fukushima, Japan
S. MONODCA, Manchester, UK
M. MUELLER, Villingen-Schwenningen, Germany
F. M. MUGGA, New York, NY, USA
M. NAKAMURA, Kanazawa, Ishikawa, Japan
R. NARAYANAN, Boca Raton, FL, USA
K. NILSSON, Uppsala, Sweden
S. PATHAK, Houston, TX, USA
J. L. PERSSON, Malmo, Sweden
G. J. PILKINGTON, Portsmouth, UK
C. D. PLATOSOUCAS, Norfolk, VA, USA
A. POLLIAK, Jerusalem, Israel
R. RADES, Lubeck, Germany
M. RIGAUD, Limoges, France
U. RINGBORG, Stockholm, Sweden
M. ROSELL, Rome, Italy
S. T. ROSEN, Duarte, CA, USA
A. SCHAUER, Gottingen, Germany
M. SCHNEIDER, Wuppertal, Germany
J. SEHOUIL, Berlin, Germany
A. SETHI, Toronto, ON, Canada
G. V. SCREMBRETT, Newcastle-upon-Tyne, UK
A. SLOMINSKY, Birmingham, AL, USA
G. I. SOMA, Kagawa, Japan
G. S. STEIN, Burlington, VT, USA
T. STIBBRAND, Umeå, Sweden
T. M. THEOPHANIDES, Athens, Greece
P. M. UELAND, Bergen, Norway
H. VAN VLERBREGHE, Ghent, Belgium
R. G. VILE, Rochester, MN, USA
M. WELLER, Zurich, Switzerland
J. WESTERMARK, Turku, Finland
B. WESTERMARK, Uppsala, Sweden
Y. YEN, Taipei, Taiwan, ROC
M. R. YOUNG, Charleston, SC, USA
B. ZUMOFF, New York, NY, USA
G. J. DELINASIOS, Athens, Greece
Managing Editor: editor@iiar-anticancer.org
Managing Editor: editor@iiar-anticancer.org
ANTICANCER RESEARCH supports: (a) the establishment and the activities of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR; Kapandriti, Atiki, Greece); and (b) the organization of the International Conferences of Anticancer Research. The IIAR is a member of UIICC. For more information about ANTICANCER RESEARCH, UIAR and the Conferences, please visit the IIAR website: www.iiar-anticancer.org


Copyright: On publication of a manuscript in AR, which is a copyrighted publication, the legal ownership of all published parts of the paper passes from the Author(s) to the Journal.

Annual Subscription Rates 2018 per volume:
Institutional subscription US$ 1,098.00 (online) or US$ 2,277.00 (print & online).
Personal subscription US$ 897.00 (online) or US$ 1,277.00 (print & online).
Prices include rapid delivery and insurance. The complete previous volumes of Anticancer Research (Vol. 1-37, 1981-2017) are available at 50% discount on the above rates.

Subscription Orders: Orders can be placed at agencies, bookstores, or directly with the Publisher. (e-mail: subscriptions@iiar-anticancer.org)

Advertising: All correspondence and rate requests should be addressed to the Editorial Office.

Book Reviews: Recently published books and journals should be sent to the Editorial Office. Reviews will be published within 2-4 months.


Obtaining permission to reuse or reproduce our content: AR has partnered with Copyright Clearance Center (CCC) to make it easy to secure permissions to reuse its content. Please visit www.copyright.com and enter the title that you are requesting permission for in the "Get Permission" search box. For assistance in placing a permission request, Copyright Clearance Center can be contacted directly at: Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923 USA. Phone +1-978-750-8400. Fax: +1-978-646-8600. E-mail: info@copyright.com.

The Editors and Publishers of ANTICANCER RESEARCH accept no responsibility for the opinions expressed by the contributors or for the content of advertisements appearing therein.

Copyright © 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

D.T.P. BY IIAR
PRINTED BY ENTYPO, ATHENS, GREECE. PRINTED ON ACID-FREE PAPER.
Announcement - Call for Papers

Special Issue of ANTICANCER RESEARCH 2019 on NEW ANTICANCER AGENTS

TOPICS:

A. Experimental Studies on “New Anticancer Agents”
   1. Synthesis and evaluation in vitro and in vivo
   2. Mechanism of action
   3. Reversal of resistance to anticancer agents

B. Clinical Studies on “New Anticancer Agents”
   1. Pharmacology
   2. Phase I and II Studies
   3. Combination chemotherapy
   4. Immunotherapeutic agents
   5. New methodologies in drug delivery and therapy

Deadline for submission of original and review articles: April 10, 2019
Publication date: July 2019

Information:
Dr. George J. Delinasios, e-mail: journals@iiar-anticancer.org
8th. INTERAMERICAN ONCOLOGY CONFERENCE

CURRENT STATUS AND FUTURE OF ANTI-CANCER THERAPIES

October 17-18 2019

FACULTY
Alex A. Adjei, Rochester, USA
Kenneth C. Anderson, Boston, USA
Stephen M. Ansell, Rochester, USA
Carlos L. Arteaga, Dallas, USA
Carlos H. Barrios, Porto Alegre, Brazil
Joaquim Bellmunt, Boston, USA
Jorge Cortés, Houston, USA
Charles Drake, NY, USA
Román Pérez Soler, Bronx, USA
Gabriel A. Rabinovich, B. A., Argentina
Antoni Ribas, Los Angeles, USA
Josep Tabernero, Barcelona, Spain

PRELIMINARY PROGRAM
New Anticancer Therapies
Biomarkers
Immunotherapies
Melanoma
Breast Cancer
Genitourinary Cancer
Gastrointestinal Cancer
Lung Cancer
Hematological Malignancies

Universidad Católica Argentina
San José Building
Juan Pablo II Meeting Room
Puerto Madero
Buenos Aires, Argentina

www.oncologyconferences.com.ar
CANCER GENOMICS & PROTEOMICS

Welcome to Submissions of Original High Quality Articles and Reviews on All Aspects of the Application of Genomic and Proteomic Technologies to Experimental and Clinical Cancer Research. The journal's scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development.

A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 1-3 months from submission.

CGP is published bimonthly by the International Institute of Anticancer Research (IIAR) and is available online only and open access with Stanford University HighWire Press. For more information please visit our website www.cgp.iiarjournals.org.

Editorial Office: International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389.

U.S. Branch: Anticancer Research Inc., USA, 111 Bay Avenue, Highlands, NJ, USA.

E-mail: journals@iiar-anticancer.org; IIAR WEBSITES: www.iiar-anticancer.org and www.iiarjournals.org

Selection of Recent Articles

Multiregion Genomic Analysis of Serially Transplanted Patient-derived Xenograft Tumors. K. SATO, A. NIIDA, T. MASUDA, D. SHIMIZU, T. TOBO, Y. KURODA, H. EGUCHI, T. NAKAGAWA, Y. SUZUKI, K. MIMORI (Oita; Fukuoka; Tokyo; Chiba, Japan)

MicroRNAs as Potential Targets for Therapeutic Intervention With Metastasis of Non-small Cell Lung Cancer. U.H. WEIDLE, F. BIRZELE, A. NOPORA (Penzberg, Germany; Basel, Switzerland)

Three Poliovirus Sequences in the Human Genome Associated With Colorectal Cancer. S. LEHRER, P.H. RHEINSTEIN (New York, NY, USA)

mRNA Expression of CDK2AP1 in Human Breast Cancer: Correlation With Clinical and Pathological Parameters. R. GERA, L. MOKBEL, W.G. JIANG, K. MOKBEL (London; Cardiff, UK)

Molecular Genetic Characterization of Acute Myeloid Leukemia With Trisomy 4 as the Sole Chromosome Abnormality. S. TORKILDSEN, L. GORUNOVA, S. HEIM, G.E. TJØNNFJORD, S. SPETALEN, B. RISBERG, H.T.T. TRAN, I. PANAGOPoulos (Oslo; Lørenskog, Norway)

Isoforms of Ionotropic Glutamate Receptor GRIK2 Induce Senescence of Carcinoma Cells. V.K. ZHAWAR, R.P. KANDPAL, R.S. ATHWAL (Philadelphia, PA; Pomona, CA, USA)

Human Periprostatic Adipose Tissue: Secretome from Patients With Prostate Cancer or Benign Prostate Hyperplasia. P.A. SACCA, O.N. MAZZA, C. SCORTICATI, G. VITAGLIANO, G. CASAS, J.C. CALVO (Buenos Aires, Argentina)

MiR-1 Suppresses Proliferation of Osteosarcoma Cells by Up-regulating p21 via PAX3. R. FUJII, E. OSAKA, K. SATO, Y. TOKUHASHI (Tokyo, Japan)

NOTUM Is Involved in the Progression of Colorectal Cancer. J.H. YOON, D. KIM, J. KIM, H. LEE, J. GHIM, B.J. KANG, P. SONG, S.H. RYU, T.G. LEE (Daegu; Pohang, Republic of Korea)

The Functional Role of Prostate Cancer Metastasis-related Micro-RNAs. U.H. WEIDLE, A. EPP, F. BIRZELE, U. BRINKMANN (Penzberg, Germany; Basel, Switzerland)
General Policy

IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of human physiology, pathology and disease management. A special focus of the journal is the publication of works on: (a) Experimental development and application of new diagnostic procedures; (b) Pharmacological and toxicological evaluation of new drugs and drug combinations; (c) Clinical trials; (d) Development and characterization of models of biomedical research.

The principal aim of IN VIVO is to provide prompt online publication for accepted articles, generally within 1-2 months from final acceptance (3 months from submission).

Editorial Office: International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389.

U.S. Branch: Anticancer Research Inc., USA, 111 Bay Avenue, Highlands, NJ, USA.

E-mail: journals@iiar-anticancer.org; IIAR WEBSITES: www.iiar-anticancer.org and www.iiarjournals.org

Selection of Recent Articles


A Simple and Easily Reproducible Model of Reversible Obstructive Jaundice in Rats. S. HIRATANI, R. MORI, Y. OTA, R. MATSUYAMA, T. KUMAMOTO, Y. NAGASHIMA, D. MORIOKA, I. ENDO (Yokohama, Japan)


Cytotoxicity and Pro-inflammatory Properties of Aliphatic Alpha, Beta-unsaturated Acid and Ester Monomers in RAW264.7 Cells and Their Chemical Reactivity. Y. MURAKAMI, A. KAWATA, S. SUZUKI, S. FUJISAWA (Sakado, Japan)


Mid- to Long-term Outcomes After Split-thickness Skin Graft vs. Skin Extension by Multiple Incisions. J.N. KERN, F. WEIDEMANN, P.F. O’LOUGHLIN, C. KRETTEK, R. GAULKE (Hanover, Germany; Cork, Ireland)


Reviews